Conclusively, cilta-cel is a BCMA-directed, genetically modified autologous T-cell therapy, which involves reprogramming a patient’s own T-cells with a transgene encoding a synthetic CAR receptor that identifies and eliminates BCMA expressing cancer cells. This evidence concerns the gene TNFRSF17 and cancer.